Link for #irAE trainee survey 👇 arcsapps.umassmed.edu/redcap… @HemOncFellows @hemeoncfellow

JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1 @ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert

“What is the goal for better patient preparation for IO treatments?” Join us at the @ASPIRE_CoP webinar that’s happening now!

ASPIRE, a community of practice of @ASCO is proud to present a virtual webinar on Elevating Patient Voices in the Management of irAEs. Join us today at 4 pm EST for our Quarterly Webinar series with hosts @KMittalmd and @afreenshariffmd 🔗 in flyer ⬇️

@eaonc @MonikaJoshimd

Looking forward to returning to LEAD this week! @AnaVManana @NazliDizman

After a Stage 4 prostate cancer diagnosis, Phil Berube participated in a clinical trial @UMassChan that helped make his recovery possible. Today, he's thriving and helping raise awareness for cancer research at the UMass Cancer Walk. Read his story: ow.ly/7JXH50ZO1Cj

EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with advanced #UrothelialCancer. The trial aims to improve treatment options & guide further research. ➡️ bit.ly/ea8231-study

.@MonikaJoshimd and @PGrivasMDPhD are leading #ClinicalTrial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced #UrothelialCancer. bit.ly/ea8231-study

⚡️ Systematic review on ctDNA in urothelial bladder cancer: plasma and urine liquid biopsy as diagnostic, prognostic, and predictive tools across all disease stages. ctDNA shows consistent prognostic value. Standardization of thresholds and platforms remains the key barrier to routine clinical use. euoncology.europeanurology.c… #BladderCancer @EurUrolOncol

I have been playing around with this trials finder a little and so far, I am impressed. We must find a better way to make it easier for physicians and other providers, as well as patients, to find trials and this is certainly a step in that direction. Check it out!

Excited to welcome our 2026 Urology Residency applicants to UMass Chan! 🩺 Join us for interviews Nov. 17–18. We look forward to sharing our program, team & Worcester with you! #Urology #UrologyResidency #UMassChan

Have a patient with prostate cancer who had a severe taxane allergy who could benefit from cabazitaxel? See our successful desensitization protocol here! nature.com/articles/s41391-0… @DukeGUCancer

Sad to miss out on day 1 due to being on service; so excited to attend and present tomorrow! Looking forward to learning from the best in the field!

Don’t miss the @ASPIRE_CoP quarterly case discussion Aug 18th! @afreenshariffmd @FunchainMD @lexmeara Special focus: Neuro and skin irAEs

Congrats @ggebraelmd on your very thoughtful editorial with @neerajaiims on the PSMAddition trial!

Excited to see the PSMAddition trial published in @TheLancet, on the heels of the FDA approval of ¹⁷⁷Lu-PSMA-617 for patient with PSMA+ mHSPC! Congrats @DrScottTagawa #MikeMorris on leading this effort! Proud to have been part of this landmark trial at @CleClinicMD enrolling highest number of patients in the U.S. @ChrisWeeMD @AmandaNizamMD @jamecancerdoc @MosheOrnsteinMD @caseccc @neerajaiims @montypal @PGrivasMDPhD @OncBrothers @OncoAlert @VivekSubbiah @APCCC_Lugano @Uromigos thelancet.com/journals/lance…

@eaonc @MonikaJoshimd

15 Posts Not To Miss From the 2026 Bladder Cancer Advocacy Network Think Tank @BladderCancerUS @DrOmarMian @FaltasLab @UroDocAsh @katy_beckermann @Parminder1699 @LauraBukavinaMD @PGrivasMDPhD @DrKarineTawagi @apolo_andrea @bergsa83 @akfsurgeon @BrendanGuercio @shilpaonc @DrAndreKydd oncodaily.com/not-to-miss/bc…

#BCANTT26 @BladderCancerUS Kudos to @JoshMeeks @koshkin85 for chairing a phenomenal session on EV-P in UC addressing unmet 🔥Qs about optimal Tx duration, consolidative strategies, bladder preservation, ctDNA etc. Amazing speakers @DrRosenbergMSK @UroDocAsh @SimaPorten & most importantly patient advocate Jon Treffert. Important Qs that will drive the next generation of trials to advance the field!

JUST IN: @US_FDA approves LuPSMA (Pluvicto, @Novartis) in combination with androgen receptor pathway inhibitor (ARPI) in PSMA (+) metastatic hormone-sensitive prostate cancer. Approval based on PSMAddition trial (HR PFS 0.72), immature OS.